8-K: Sera Prognostics Q3 2025: Payer Traction, Leadership Boost

Sera Prognostics reports Q3 2025 financial results, highlighting progress in payer engagement, key study publications, and strategic leadership appointments.

Summary

• Third quarter 2025 revenue was $16,000, a decrease from $29,000 for the third quarter of 2024.
• Deferred revenue increased by $100,000 as of September 30, 2025, driven by a prepayment from the first Medicaid pilot in Nevada.
• Total operating expenses for Q3 2025 were $9.0 million, up from $8.9 million for the same period in 2024.
• Research and development expenses decreased to $3.3 million in Q3 2025 from $3.5 million in Q3 2024, primarily due to lower clinical study costs following the completion of the pivotal PRIME study.
• Selling, general and administrative expenses increased to $5.7 million in Q3 2025 from $5.4 million in Q3 2024, due to investments in targeted commercial activities and strategic headcount additions.
• Net loss for the quarter was $7.8 million, a slight improvement from $7.9 million for the same period a year ago.
• As of September 30, 2025, the company had cash, cash equivalents, and available-for-sale securities of approximately $102.4 million, which is expected to fund operations through 2028.
• The company made meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, and is engaging with multiple payers across thirteen states.
• Sera Prognostics is on track to publish the full study results of its PRIME study this year, followed by additional data on health economic benefits, sub-population analysis, and Medicaid expected cost-saving benefits of the PreTRM Test.
• Dr. Tiffany Inglis was appointed as Chief Medical Officer in October, and Marisol Urbano was appointed as Head of Commercial Operations.

Sentiment

Score: 6

Explanation: While financial results show a decline in revenue and continued losses, the company reports significant progress in commercialization efforts, including a new Medicaid pilot and strong payer engagement, backed by positive PRIME study data. Strategic leadership appointments also contribute to a moderately positive outlook on future growth despite current financial performance.

Positives

• Launched an inaugural Medicaid pilot in Nevada, actively enrolling patients, signaling early market engagement.
• Engaging with multiple payers across thirteen states, representing a strong commercial opportunity covering 33% of U.S. births and 35% of Medicaid births annually.
• On track to publish full PRIME study results this year, with additional health economic and Medicaid cost-saving data to follow swiftly.
• Presented PRIME data at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe conference and the Renaissance Conference.
• Strengthened leadership team with the appointment of Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations.
• Net loss slightly improved to $7.8 million in Q3 2025 from $7.9 million in Q3 2024.
• Research and development expenses decreased due to lower clinical study costs following the completion of the pivotal PRIME study.
• Maintained a strong cash, cash equivalents, and available-for-sale securities balance of approximately $102.4 million, expected to fund the company through 2028.
• Deferred revenue increased by $100,000 due to a prepayment received from the first Medicaid pilot in Nevada.

Negatives

• Third quarter 2025 revenue decreased to $16,000 from $29,000 in the third quarter of 2024.
• Total operating expenses increased to $9.0 million in Q3 2025 from $8.9 million in Q3 2024.
• Selling, general and administrative expenses increased to $5.7 million in Q3 2025 from $5.4 million in the prior-year period.

Risks

• Net losses, cash generation, and the potential need to raise more capital.
• Revenues from the PreTRM Test representing substantially all Company revenues to date.
• The need for broad scientific and market acceptance of the PreTRM Test.
• A concentrated number of material customers.
• Ability to introduce new products.
• Potential competition.
• Reliance on proprietary biobank.
• Reliance on critical suppliers.
• Estimates of total addressable market opportunity and forecasts of market growth may be inaccurate.
• Potential third-party payer coverage and reimbursement challenges.
• New reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates.
• Changes in FDA regulation of laboratory-developed tests.
• Intellectual property rights protecting tests and market position.

Future Outlook

The company expects to publish the full study results of its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study this year, followed swiftly by additional data on health economic benefits, sub-population analysis, and Medicaid expected cost-saving benefits of the PreTRM Test. Management anticipates driving meaningful adoption in target states and beyond through ongoing engagement with managed Medicaid and other key stakeholders, including regional and national payers. The company believes its current cash, cash equivalents, and available-for-sale securities of approximately $102.4 million will fund operations across significant adoption and commercial milestones through 2028.

Management Comments

• Zhenya Lindgardt, President and CEO: "We are seeing commercial traction from the groundwork we have laid, anchored by the results from our pivotal PRIME study. These data are driving meaningful engagement with managed Medicaid and other key stakeholders, including the launch of our first Medicaid pilot in Nevada. We are also advancing discussions with managed Medicaid plans in additional states, representing a strong commercial opportunity, covering 33% of U.S. births and 35% of Medicaid births annually. Beyond this first wave, weve initiated outreach to the next tier of target states, expanding our footprint of states in discussion. In addition, we are actively engaged with payers who are both regional and national in scope. We believe these early signals of market engagement, combined with the scale of the opportunity, position us well to deliver meaningful impact for patients and long-term value for shareholders."
• Dr. Tiffany Inglis, Chief Medical Officer: "Were seeing strong early traction with payers, providers, and State Medicaid agencies, who recognize PreTRMs predictive accuracy and the 20% reduction in NICU admissions. These partners see clear potential to improve maternal and neonatal outcomes while significantly lowering costs driven by preterm birth. Securing broad coverage at the employer, plan, and state levels is the critical next step to unlocking this value at scale. We are actively advancing these discussions to drive adoption and transform prenatal care."

Industry Context

The announcement highlights Sera Prognostics' strategic efforts to address the significant public health and economic burden of preterm birth, which affects over one in ten infants in the U.S. annually and incurs approximately $25 billion in healthcare costs. The company's focus on securing broad payer coverage, particularly with Medicaid, aligns with broader trends in healthcare diagnostics seeking to demonstrate clear health economic benefits and integrate into value-based care models to improve maternal and neonatal outcomes. The PreTRM Test aims to provide early, accurate risk prediction, a critical need in precision pregnancy care, positioning the company to capitalize on the growing demand for advanced diagnostic solutions in maternal-fetal medicine.

Comparison to Industry Standards

• The PreTRM Test is positioned as the "only broadly validated, commercially available blood-based biomarker test" for early, accurate, individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies, suggesting a unique market position.
• The PRIME study results, which are driving payer engagement, demonstrated a "20% reduction in NICU admissions," a key outcome metric for neonatal care and cost savings, which is a significant clinical and economic benefit.
• The company is targeting a substantial market opportunity, engaging with payers in states covering "33% of U.S. births and 35% of Medicaid births annually," indicating a focus on a large and impactful segment of the population compared to niche diagnostic markets.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through increased market adoption and revenue expansion, but current financial performance (declining revenue, ongoing losses) presents short-term concerns. The strong cash position provides a substantial runway through 2028.
• Patients (Mothers and Newborns): Improved maternal and neonatal health outcomes through early prediction of preterm birth risk and proactive interventions enabled by the PreTRM Test.
• Healthcare Providers (Doctors): Access to innovative pregnancy biomarker information for more informed, personalized clinical decisions based on each woman's individual risk.
• Payers (Medicaid, Insurers): Potential for significant cost savings driven by a 20% reduction in NICU admissions and improved outcomes from the PreTRM Test, aligning with value-based care initiatives.
• Employees: Strategic headcount additions and investment in commercial activities indicate growth opportunities and a focus on expanding the team.

Next Steps

• Publish the full study results of the PRIME study this year.
• Swiftly publish additional data on health economic benefits, sub-population analysis, and Medicaid expected cost-saving benefits of the PreTRM Test.
• Continue advancing discussions with managed Medicaid plans in additional states.
• Continue active engagement with regional and national payers to secure broad coverage at employer, plan, and state levels.
• Accelerate customer onboarding and clinical integration for the PreTRM Test.

Key Dates

Recommendation

While the company's current financial performance shows declining revenue and continued losses, the strategic progress in payer engagement, particularly with Medicaid, and the upcoming publication of pivotal study data (PRIME) are significant catalysts for future growth. The strong cash position provides a substantial runway through 2028, mitigating immediate liquidity concerns. The leadership appointments also strengthen the commercialization efforts. However, the current revenue decline and ongoing operating losses suggest that widespread adoption and revenue expansion are still in early stages. An investor should hold to monitor the execution of commercial strategies and the impact of the PRIME study data on payer coverage and reimbursement.

Keywords

Sera Prognostics, SERA, PreTRM Test, preterm birth, pregnancy diagnostics, maternal health, neonatal health, biomarker, Medicaid, payer engagement, PRIME study, financial results, Q3 2025, medical technology, diagnostics